Lighting up only the immune cells that matter
Asher Biotherapeutics (asherbio.com) earns a Brand Analyzer score of 66 out of 100, placing it in the Developing tier among Healthcare brands. Among 2305 Healthcare brands analyzed, Asher Biotherapeutics ranks in the 37th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 85/100, Digital Presence 76/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 69/100, AI Discoverability 77/100, Brand Authority 8/100.
Asher Biotherapeutics is a biotechnology company developing cis-targeted immunotherapies that selectively activate specific immune cell types to treat cancer and other diseases. Unlike conventional immunotherapies that act indiscriminately across multiple cell types, Asher's approach engages two molecules on the same immune cell for precise activation. Its lead clinical candidate, etakafusp alfa, targets CD8+ T cells and has demonstrated anti-tumor activity in clinical trials.
| Brand Name | Asher Biotherapeutics |
|---|---|
| Domain | asherbio.com |
| Industry | Healthcare |
| Main Competitors | Nektar Therapeutics, Syndax Pharmaceuticals, Agenus, Inhibrx, Werewolf Therapeutics |
Moz Domain Authority 25/100 vs category average 29 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "At Asher Biotherapeutics, we are pioneering a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the…" (Meta description: 53 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, Instagram, GitHub; no detected presence on X (Twitter), Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Asher Biotherapeutics scores 18/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Asher Biotherapeutics has a weak AI-visibility profile at 18/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 25/100.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Asher Biotherapeutics's main competitors include Nektar Therapeutics, Syndax Pharmaceuticals, Agenus, Inhibrx, Werewolf Therapeutics. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Asher Biotherapeutics official site
Popular alternatives to Asher Biotherapeutics include Nektar Therapeutics, Syndax Pharmaceuticals, Agenus, Inhibrx, Werewolf Therapeutics. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics' primary product in development is etakafusp alfa, a clinical-stage molecule that cis-targets CD8+ T cells to drive anti-tumor immune responses. More broadly, the company's pipeline is built around its cis-targeted immunotherapy platform, which is designed to engage two molecules on the same immune cell for selective activation. These are investigational therapeutics intended for cancer and potentially other diseases where targeted immunotherapy may be beneficial.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics has low AI-search visibility, scoring 18/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 23, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics develops cis-targeted immunotherapies that engage two molecules on the same immune cell simultaneously, enabling precise and selective immune cell activation. This approach is intended to optimize therapeutic efficacy while minimizing toxicity compared to conventional immunotherapies. The company is advancing clinical-stage molecules, including its lead candidate etakafusp alfa, which specifically targets CD8+ T cells and has shown anti-tumor activity in clinical trials.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics is a biotechnology company pioneering cis-targeted immunotherapies. Its platform is designed to selectively activate only the immune cell types that drive a desired therapeutic response, addressing a core limitation of conventional immunotherapies, which act indiscriminately on multiple cell types and can result in suboptimal efficacy and unwanted side effects. The company focuses on cancer and other diseases where targeted immune activation may offer therapeutic benefit.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics and Nektar Therapeutics are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics is known for its cis-targeted immunotherapy platform, which selectively activates specific immune cell populations rather than broadly acting on multiple cell types. The company is particularly associated with etakafusp alfa, its lead clinical molecule that targets CD8+ T cells for anti-tumor activity. This cis-targeting mechanism distinguishes Asher from developers of conventional immunotherapies by aiming to improve both selectivity and the therapeutic window.
Sources: Asher Biotherapeutics official site
Asher Biotherapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Asher Biotherapeutics official site
Based on the known facts, Asher Biotherapeutics' therapies are aimed at patients with cancer and other diseases that may be addressed through targeted immunotherapy. As the company's candidates, including etakafusp alfa, are in clinical trials, current users would primarily be clinical trial participants. Healthcare professionals and researchers in oncology and immunotherapy are also relevant stakeholders who engage with the company's platform and data.
Sources: Asher Biotherapeutics official site
Ranked closest to Asher Biotherapeutics: Altermed RCM (66/100), Alliance Enterprises (66/100), Azara Healthcare (66/100), BettrAi (66/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Dassault Systèmes (95/100).